Literature DB >> 11687510

Aspirin-triggered lipoxin A4 and lipoxin A4 up-regulate transcriptional corepressor NAB1 in human neutrophils.

F H Qiu1, P R Devchand, K Wada, C N Serhan.   

Abstract

Aspirin-triggered 15-epi-lipoxin A4 (ATL) is an endogenous lipid mediator that mimics the actions of native lipoxin A4, a putative "stop signal" involved in regulating resolution of inflammation. A metabolically more stable analog of ATL, 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4 analog (ATLa), inhibits neutrophil recruitment in vitro and in vivo and displays potent anti-inflammatory actions. ATLa binds with high affinity to the lipoxin A4 receptor, a G protein-coupled receptor on the surface of leukocytes. In this study, we used freshly isolated human neutrophils to examine ATLa's potential for initiating rapid nuclear responses. Using differential display reverse transcription polymerase chain reaction, we identified a subset of genes that was selectively up-regulated upon short exposure of polymorphonuclear leukocytes to ATLa but not to the chemoattractant leukotriene B4 or vehicle alone. We further investigated ATLa regulation of one of the genes, NAB1, a transcriptional corepressor identified previously as a glucocorticoid-responsive gene in hamster smooth muscle cells. Treatment of human neutrophils with pertussis toxin blocked ATLa up-regulation of NAB1. In addition, ATLa stimulated NAB1 gene expression in murine lung vascular smooth muscle in vivo. These findings provide evidence for rapid transcriptional induction of a cassette of genes via an ATLa-stimulated G protein-coupled receptor pathway that is potentially protective and overlaps with the anti-inflammatory glucocorticoid regulatory circuit.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11687510     DOI: 10.1096/fj.01-0576fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  16 in total

1.  Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature.

Authors:  Vincenzo Brancaleone; Jesmond Dalli; Stefania Bena; Roderick J Flower; Giuseppe Cirino; Mauro Perretti
Journal:  J Immunol       Date:  2011-03-11       Impact factor: 5.422

2.  Development of a genetic marker set to diagnose aspirin-exacerbated respiratory disease in a genome-wide association study.

Authors:  H S Chang; S W Shin; T H Lee; D J Bae; J S Park; Y H Kim; S T Uh; B W Choi; M K Kim; I S Choi; B L Park; H D Shin; C S Park
Journal:  Pharmacogenomics J       Date:  2015-02-24       Impact factor: 3.550

Review 3.  Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense.

Authors:  John L Wallace; Pallavi R Devchand
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

4.  Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells.

Authors:  Karen Rodgers; Blaithin McMahon; Derick Mitchell; Denise Sadlier; Catherine Godson
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

Review 5.  A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution.

Authors:  Charles N Serhan
Journal:  Histochem Cell Biol       Date:  2004-08-21       Impact factor: 4.304

Review 6.  Lipoxins: resolutionary road.

Authors:  Paola Maderna; Catherine Godson
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

Review 7.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

8.  A novel rat lipoxin A4 receptor that is conserved in structure and function.

Authors:  Nan Chiang; Tomoko Takano; Makoto Arita; Shiro Watanabe; Charles N Serhan
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

9.  Ubenimex Suppresses the Ability of Migration and Invasion in Gastric Cancer Cells by Alleviating the Activity of the CD13/NAB1/MAPK Pathway.

Authors:  Xuehui Liu; Qie Guo; FanJing Jing; ChangKai Zhou; Ting Xiu; YunYan Shi; FanBo Jing
Journal:  Cancer Manag Res       Date:  2021-06-04       Impact factor: 3.989

10.  Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals.

Authors:  Charles N Serhan; Song Hong; Karsten Gronert; Sean P Colgan; Pallavi R Devchand; Gudrun Mirick; Rose-Laure Moussignac
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.